Geninus Inc is a Korea-based company principally engaged in the bioinformatics analysis business. The Company is engaged in the provision of single cell analysis services, genetic testing for disease prediction for the public, cancer genome analysis solutions based on tissue biopsy and other services. It is also engaged personal genetic testing, software development, rental business and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-14	₩2,215.00	-4.53%	208,013
26-08-13	₩2,320.00	-2.73%	303,123
26-08-12	₩2,385.00	+0.21%	172,908
26-08-11	₩2,380.00	+1.28%	207,730
26-08-10	₩2,350.00	+8.29%	247,378

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. 2026-08-14			5-day change	1st Jan Change
2,215.00 ^KRW	-4.53%		+2.07%	-36.71%

03-24	GENINUS Inc. announced that it has received KRW 19.999993583 billion in funding from KB Investment Co., Ltd, Company K Partners Limited	CI
03-05	GENINUS Inc. announced that it expects to receive KRW 19.999993583 billion in funding from KB Investment Co., Ltd, Company K Partners Limited	CI

Market Cap	87.25B 61.73M 53.31M 50.1M 45.56M 85.66M 5.9B 87.07M 587M 230M 2.96B 232M 227M 9.82B	P/E 2024	-3.73x	P/E 2025	-6.72x
Enterprise Value	82.77B 58.55M 50.57M 47.52M 43.22M 81.25M 5.6B 82.59M 557M 218M 2.8B 220M 215M 9.32B	EV / Sales 2024	6.46x	EV / Sales 2025	10.7x
Free-Float	73.5%	Yield 2024 *	-	Yield 2025	-

03-24	GENINUS Inc. announced that it has received KRW 19.999993583 billion in funding from KB Investment Co., Ltd, Company K Partners Limited	CI
03-05	GENINUS Inc. announced that it expects to receive KRW 19.999993583 billion in funding from KB Investment Co., Ltd, Company K Partners Limited	CI
25-05-21	GENINUS Inc. announced that it has received KRW 10 billion in funding from AJU IB INVESTMENT Co., Ltd., Korea Investment & Securities Co., Ltd., Korea Investment Partners Co. Ltd. and other investors	CI
25-05-18	GENINUS Inc. announced that it expects to receive KRW 10 billion in funding from AJU IB INVESTMENT Co., Ltd., Korea Investment & Securities Co., Ltd., Korea Investment Partners Co. Ltd. and other investors	CI
21-11-01	GENINUS Inc. has completed an IPO in the amount of KRW 40 billion.	CI
21-07-08	GENINUS Inc. has filed an IPO.	CI

1 day	-4.53%
1 week	+2.07%
Current month	+9.93%
1 month	-1.34%
3 months	-43.71%
6 months	-28.43%
Current year	-36.71%

GENINUS Inc. Stock

Stocks

A389030

KR7389030008

Biotechnology & Medical Research

Valuation: GENINUS Inc.

Chart: GENINUS Inc.

Latest news : GENINUS Inc.

Quotes and Performance

Course Extremes

Managers and Directors: GENINUS Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	2,170	2,450
1 month	1,771	2,450
Current year	1,771	6,480
1 year	1,490	6,480
3 years	1,080	6,480
5 years	1,080	6,483.33
10 years	1,080	6,483.33

Manager	Title	Age	Since
Woong-Yang Park CEO	Chief Executive Officer	63	2018-03-31
Jong-Myeon Park CTO	Chief Tech/Sci/R&D Officer	53	-
Hyeon-Mi Do CTO	Chief Tech/Sci/R&D Officer	54	-

Director	Title	Age	Since
Woong-Yang Park BRD	Director/Board Member	63	2018-03-31
Jung-Kyu Han BRD	Director/Board Member	63	-
Sang-Hyeok Lee BRD	Director/Board Member	63	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/30/24	Sang-Hyeok Lee	Buy	Director	1,000	0.0030%
1/30/24	Sang-Hyeok Lee	Buy	Director	1,000	0.0030%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENINUS INC.	-4.53%	+2.07%	+27.23%	-58.52%	61.73M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+1.14%	-0.76%	+89.72%	+293.32%	3.95B
VERACYTE, INC.	-3.17%	-12.64%	+36.50%	+64.80%	3.32B
IOVANCE BIOTHERAPEUTICS, INC.	+7.06%	+10.09%	+173.73%	-7.06%	3.16B
CAREDX, INC.	-4.35%	-2.93%	+282.77%	+369.15%	2.34B
BGI GENOMICS CO., LTD.	-3.10%	+1.70%	-21.24%	-25.97%	2.31B
FREENOME, INC.	-0.43%	+3.68%	+9.37%	-	1.3B
SEEGENE, INC.	+0.78%	+11.25%	+15.23%	+49.19%	1.04B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-1.38%	-8.51%	+118.39%	-45.09%	849M
CURIOX BIOSYSTEMS CO., LTD	+29.91%	+22.82%	-6.81%	+358.96%	616M
Average	+2.19%	+0.19%	+72.49%	+110.98%	1.9B
Weighted average by Cap.	+0.85%	-0.65%	+93.11%	+135.23%

	2024	2025
Net sales	6.46B 4.57M 3.94M 3.71M 3.37M 6.34M 437M 6.44M 43.43M 16.98M 219M 17.15M 16.77M 727M	10.48B 7.42M 6.41M 6.02M 5.47M 10.29M 709M 10.46M 70.53M 27.58M 355M 27.84M 27.24M 1.18B
Net income	-12.27B -8.68M -7.5M -7.05M -6.41M -12.05M -830M -12.25M -82.57M -32.28M -416M -32.6M -31.89M -1.38B	-17.37B -12.29M -10.62M -9.98M -9.07M -17.06M -1.18B -17.34M -117M -45.7M -589M -46.14M -45.14M -1.96B
Net Debt	-4.14B -2.93M -2.53M -2.38M -2.16M -4.07M -280M -4.13M -27.86M -10.89M -140M -11M -10.76M -466M	-4.49B -3.17M -2.74M -2.58M -2.34M -4.41M -304M -4.48M -30.19M -11.8M -152M -11.92M -11.66M -505M